STOCK TITAN

Nasus Pharma grants CFO Nir Sassi options on 115K shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
3

Rhea-AI Filing Summary

Nasus Pharma Ltd CFO Nir Sassi was granted options to purchase 115,000 ordinary shares under the company’s 2019 Incentive Option Plan on November 11, 2026. The options have exercise prices of $3.50 for 38,333 shares, $4.00 for 38,333 shares, and $5.00 for 38,334 shares. Vesting spans 36 months: one-third on November 11, 2027, then the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. The options expire November 11, 2036.

Insider Sassi Nir
Role Chief Financial Officer
Type Security Shares Price Value
Holding Share options (right to buy) F1 -- -- --
Holding Share options (right to buy) F1 -- -- --
Holding Share options (right to buy) F1 -- -- --
Holdings: Share options (right to buy) — 115,000 options (Direct)
Footnotes (1)
  1. F1. On November 11, 2026, the Issuer granted options to purchase 115,000 ordinary shares, no par value ("Ordinary Shares"), under its 2019 Incentive Option Plan. The options vest over thirty-six (36) months: one-third on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. Any fractional shares resulting from vesting will be deferred to the next vesting tranche on a rolling basis.
Option award 115,000 ordinary shares Granted November 11, 2026, under the 2019 Incentive Option Plan
Options at $3.50 exercise price 38,333 ordinary shares Options granted November 11, 2026
Options at $4.00 exercise price 38,333 ordinary shares Options granted November 11, 2026
Options at $5.00 exercise price 38,334 ordinary shares Options granted November 11, 2026
Vesting period 36 months One-third vests November 11, 2027; remaining two-thirds vest in eight equal quarterly installments beginning February 11, 2028
Exercise price $3.50 per share Applies to options for 38,333 ordinary shares
Exercise price $4.00 per share Applies to options for 38,333 ordinary shares
Exercise price $5.00 per share Applies to options for 38,334 ordinary shares
2019 Incentive Option Plan financial
"under its 2019 Incentive Option Plan"
vesting financial
"The options vest over thirty-six (36) months"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
quarterly installments financial
"in eight equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did Nasus Pharma (NSRX) CFO Nir Sassi receive?

Nir Sassi was granted options to purchase 115,000 ordinary shares under the company’s 2019 Incentive Option Plan on November 11, 2026.

When do Nir Sassi’s Nasus Pharma (NSRX) options vest?

The options vest over 36 months, with one-third vesting on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Sassi Nir

(Last)(First)(Middle)
P.O. BOX 284

(Street)
TEL-AVIV-YAFO6100201

(City)(State)(Zip)

ISRAEL

(Country)
2. Date of Event Requiring Statement (Month/Day/Year)
11/11/2026
3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Share options (right to buy)(1)11/11/202711/11/2036Ordinary Shares38,333$3.5D
Share options (right to buy)(1)02/11/202811/11/2036Ordinary Shares38,333$4D
Share options (right to buy)(1)02/11/202811/11/2036Ordinary Shares38,334$5D
Explanation of Responses:
1. On November 11, 2026, the Issuer granted options to purchase 115,000 ordinary shares, no par value ("Ordinary Shares"), under its 2019 Incentive Option Plan. The options vest over thirty-six (36) months: one-third on November 11, 2027, and the remaining two-thirds in eight equal quarterly installments beginning February 11, 2028. Any fractional shares resulting from vesting will be deferred to the next vesting tranche on a rolling basis.
/s/ Nir Sassi11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Keep reading